(RTTNews) - AstraZeneca (AZN) said Tuesday that full results from the Phase 3 CROSSING trial showed Tezspire improved disease remission and swallowing symptoms in adolescents and adults with eosinophilic esophagitis.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.